COVID-19Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
Key words
Inborn errors of immunity
IEI
primary immunodeficiency disorders
PIDD
SARS-CoV-2
COVID-19
vaccine
Pfizer-BioNTech
CVID
XLA
NFKB1
STAT1-GOF
STAT3-LOF
HIES
inhibiting antibodies
Abbreviations used
ACE2
Angiotensin-converting enzyme 2
ALPS
Autoimmune lymphoproliferative syndrome
anti-N
Antinucleocapsid
anti-S
Antispike
AU
Arbitrary unit
AUC
Area under the curve
CID
Combined immunodeficiency
COVID-19
Coronavirus disease 2019
CVID
Common variable immunodeficiency
IEI
Inborn errors of immunity
IVIG
Intravenous immunoglobulin
NF-κB1
Nuclear factor-κB1
NFKB1-HI
Nuclear factor-κB1 haploinsufficiency
RBD
Receptor-binding domain
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
STAT
Signal transducer and activator of translation
STAT1-GOF
STAT1 gain-of-function
XLA
X-linked agammaglobulinemia
Cited by (0)
Supported by the Israel Science Foundation (grants 41222/18 and 3711/20 [to N.T.F.]), the Dahlia Greidinger Cancer Fund (to N.T.F.), a Marguerite Stolz Fellowship (N.T.F.), The Campbell Foundation for AIDS Research (to N.T.F.), and the Alrov Foundation (to D.H.).
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.
© 2021 American Academy of Allergy, Asthma & Immunology